Neurocrine/$NBIX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Neurocrine
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
- Ticker
- $NBIX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,500
- Headquarters
- San Diego, United States
- Website
- www.neurocrine.com
Neurocrine Metrics
BasicAdvanced
$15B
21.41
$6.82
0.38
-
Price and volume
Market cap
$15B
Beta
0.38
52-week high
$186.12
52-week low
$122.14
Average daily volume
1.3M
Financial strength
Current ratio
1.872
Quick ratio
1.46
Long term debt to equity
0.109
Total debt to equity
0.109
Interest coverage (TTM)
301.62%
Profitability
EBITDA (TTM)
913.3
Gross margin (TTM)
64.48%
Net profit margin (TTM)
20.91%
Operating margin (TTM)
25.67%
Effective tax rate (TTM)
24.96%
Revenue per employee (TTM)
$1,350,000
Management effectiveness
Return on assets (TTM)
11.82%
Return on equity (TTM)
22.09%
Valuation
Price to earnings (TTM)
21.413
Price to revenue (TTM)
4.341
Price to book
4
Price to tangible book (TTM)
15.27
Price to free cash flow (TTM)
16.827
Free cash flow yield (TTM)
5.94%
Free cash flow per share (TTM)
8.682
Growth
Revenue change (TTM)
34.42%
Earnings per share change (TTM)
101.21%
3-year revenue growth (CAGR)
26.34%
10-year revenue growth (CAGR)
71.87%
3-year earnings per share growth (CAGR)
57.74%
10-year earnings per share growth (CAGR)
16.93%
What the Analysts think about Neurocrine
Analyst ratings (Buy, Hold, Sell) for Neurocrine stock.
Analyst projections of the future price of Neurocrine stock.
Bulls say / Bears say
INGREZZA remains a strong growth engine: second-quarter sales rose 15% year on year, and Neurocrine raised its 2026 sales guidance after record new-patient additions. (PR Newswire)
CRENESSITY is gaining traction, with second-quarter sales reaching $184 million from $53 million a year earlier. Only about 15% of the diagnosed patient population had been prescribed it, leaving room for further uptake. (PR Newswire)
The pipeline could add new growth drivers: Neurocrine expects Phase 3 readouts in 2027 for osavampator in major depression and direclidine in schizophrenia. (PR Newswire)
INGREZZA faces a pricing headwind as Medicare price negotiations take effect for a competing drug in 2027, ahead of INGREZZA’s own negotiated price in 2029. Neurocrine has flagged that price concessions may weigh on sales despite continued volume growth. (American Banking News, earningscalls.dev)
VYKAT XR has faced reports of serious adverse events, including deaths, which could undermine uptake. The reports do not establish that the drug caused those events, but the safety concern remains a commercial risk. (Seeking Alpha)
Neurocrine paid $2.9 billion in cash for Soleno, so the acquisition creates integration and execution risk. The company has warned that expected benefits may not materialise as planned and that VYKAT XR uptake could be slower than expected. (PR Newswire)
Data summarised monthly by Lightyear AI. Last updated on 13 Oct 2026.
Neurocrine Financial Performance
Revenues and expenses
Neurocrine Earnings Performance
Company profitability
Upcoming events
No upcoming events
Neurocrine News
AllArticlesVideos
Funds containing Neurocrine
AllUSDEURGBP
Fund name | Fund size | $NBIX weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 1.01% |
iShares Healthcare Innovation€2B78 | $1.2B | 1.01% |
iShares Healthcare Innovation$HEAL | $1.3B | 1.01% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.95% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.95% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.